Evolutionary dynamics of carcinogenesis and why targeted therapy does not work

[1]  Y. Bae,et al.  Cancer nanomedicines targeting tumor extracellular pH. , 2012, Colloids and surfaces. B, Biointerfaces.

[2]  Robert J Gillies,et al.  Systemic buffers inhibit carcinogenesis in TRAMP mice. , 2012, The Journal of urology.

[3]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[4]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[5]  Noboru Niki,et al.  Quantitative classification based on CT histogram analysis of non-small cell lung cancer: correlation with histopathological characteristics and recurrence-free survival. , 2012, Medical physics.

[6]  Ben J. Boyd,et al.  Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models. , 2012, Molecular pharmaceutics.

[7]  Ben Lehner,et al.  Fitness Trade-Offs and Environmentally Induced Mutation Buffering in Isogenic C. elegans , 2012, Science.

[8]  Damien J. Ferraro,et al.  Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer , 2011, Clinical Cancer Research.

[9]  Prabhjot Kaur,et al.  Chromosomal Instability Substantiates Poor Prognosis in Patients with Diffuse Large B-cell Lymphoma , 2011, Clinical Cancer Research.

[10]  P. Glazer,et al.  Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302 , 2011, Molecular Cancer Therapeutics.

[11]  Carlo C. Maley,et al.  Overlooking Evolution: A Systematic Analysis of Cancer Relapse and Therapeutic Resistance Research , 2011, PloS one.

[12]  I. Navarro-Teulon,et al.  Clinical radioimmunotherapy—the role of radiobiology , 2011, Nature Reviews Clinical Oncology.

[13]  R. Gillies,et al.  Drug resistance and cellular adaptation to tumor acidic pH microenvironment. , 2011, Molecular pharmaceutics.

[14]  Chih-kuan Tung,et al.  Acceleration of Emergence of Bacterial Antibiotic Resistance in Connected Microenvironments , 2011, Science.

[15]  P. Fasching,et al.  Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Gillies,et al.  Reduction of metastasis using a non-volatile buffer , 2011, Clinical & Experimental Metastasis.

[17]  M. Agulnik.  New Developments in Mammalian Target of Rapamycin Inhibitors for the Treatment of Sarcoma , 2011, Cancer.

[18]  Matthew P. Jacobson,et al.  Dysregulated pH: a perfect storm for cancer progression , 2011, Nature Reviews Cancer.

[19]  P. Sutphin,et al.  Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality , 2011, Science Translational Medicine.

[20]  N. Socci,et al.  Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling , 2011, Science Translational Medicine.

[21]  Robert J Gillies,et al.  Imaging pH and metastasis , 2011, NMR in biomedicine.

[22]  Lei Xu,et al.  Normalization of the vasculature for treatment of cancer and other diseases. , 2011, Physiological reviews.

[23]  Stephen J. Chanock,et al.  Current status of genome-wide association studies in cancer , 2011, Human Genetics.

[24]  P. Glazer,et al.  Hypoxia-Induced Epigenetic Regulation and Silencing of the BRCA1 Promoter , 2011, Molecular and Cellular Biology.

[25]  J. Otsuka.  The large-scale evolution by generating new genes from gene duplication; similarity and difference between monoploid and diploid organisms. , 2011, Journal of theoretical biology.

[26]  W. Wilson,et al.  Targeting hypoxia in cancer therapy , 2011, Nature Reviews Cancer.

[27]  L. Loeb,et al.  Human cancers express mutator phenotypes: origin, consequences and targeting , 2011, Nature Reviews Cancer.

[28]  P. Carmeliet,et al.  Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? , 2011, Nature Reviews Clinical Oncology.

[29]  Joel s. Brown,et al.  Of cancer and cave fish , 2011, Nature Reviews Cancer.

[30]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[31]  T. Ono,et al.  The mechanisms of UV mutagenesis. , 2011, Journal of radiation research.

[32]  C. Lineweaver,et al.  Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors , 2011, Physical biology.

[33]  M. Dewhirst,et al.  Molecular Imaging of Hypoxia , 2011, The Journal of Nuclear Medicine.

[34]  K. Barrett,et al.  Expression of acid‐sensing ion channels in intestinal epithelial cells and their role in the regulation of duodenal mucosal bicarbonate secretion , 2011, Acta physiologica.

[35]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[36]  P. Glazer,et al.  The tumor microenvironment and DNA repair. , 2010, Seminars in radiation oncology.

[37]  M. Gerlinger,et al.  How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine , 2010, British Journal of Cancer.

[38]  R. Loffroy,et al.  3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. , 2010, Current pharmaceutical biotechnology.

[39]  N. Forbes,et al.  Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic response , 2010, British Journal of Cancer.

[40]  D. Jayne,et al.  Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells , 2010, British Journal of Cancer.

[41]  P. Gutin,et al.  Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma , 2009, Neurology.

[42]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[43]  J. Baselga,et al.  Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  T. Halazonetis,et al.  Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.

[45]  P. Houghton.  Everolimus: Fig. 1. , 2010 .

[46]  G. Semenza,et al.  Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression , 2010, Proceedings of the National Academy of Sciences.

[47]  T. Griffith,et al.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. , 2009, European journal of pharmacology.

[48]  S. Spechler,et al.  In benign Barrett's epithelial cells, acid exposure generates reactive oxygen species that cause DNA double-strand breaks. , 2009, Cancer research.

[49]  T. Vincent,et al.  Lessons from applied ecology: cancer control using an evolutionary double bind. , 2009, Cancer research.

[50]  K. Kinzler,et al.  Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells , 2009, Science.

[51]  J. Chatal,et al.  Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors. , 2009, Journal of cancer research and therapeutics.

[52]  Brandon Whitcher,et al.  Quantifying spatial heterogeneity in dynamic contrast‐enhanced MRI parameter maps , 2009, Magnetic resonance in medicine.

[53]  B. Aggarwal,et al.  Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe , 2009, Clinical Cancer Research.

[54]  C. Vogel,et al.  Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  J. Mackey,et al.  Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer , 2008, British Journal of Cancer.

[56]  B. Aggarwal,et al.  Cancer is a Preventable Disease that Requires Major Lifestyle Changes , 2008, Pharmaceutical Research.

[57]  H. Lage.  An overview of cancer multidrug resistance: a still unsolved problem , 2008, Cellular and Molecular Life Sciences.

[58]  Robert J. Gillies,et al.  Causes and Consequences of Increased Glucose Metabolism of Cancers , 2008, Journal of Nuclear Medicine.

[59]  Kenneth A Krohn,et al.  Molecular Imaging of Hypoxia , 2008, Journal of Nuclear Medicine.

[60]  Rakesh K. Jain,et al.  Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer , 2008, Nature Reviews Cancer.

[61]  Martin A. Nowak,et al.  Comparative lesion sequencing provides insights into tumor evolution , 2008, Proceedings of the National Academy of Sciences.

[62]  Richard P. Hill,et al.  Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability , 2008, Nature Reviews Cancer.

[63]  R. Hoffman,et al.  Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. , 2008, Journal of medicinal chemistry.

[64]  J. Engelman,et al.  Acquired resistance to tyrosine kinase inhibitors during cancer therapy. , 2008, Current opinion in genetics & development.

[65]  Charles M. Perou,et al.  Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution , 2008, Clinical Cancer Research.

[66]  E. Petricoin,et al.  Proteins, drug targets and the mechanisms they control: the simple truth about complex networks , 2007, Nature Reviews Drug Discovery.

[67]  R. Gillies,et al.  Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? , 2007, Journal of bioenergetics and biomembranes.

[68]  M. Koltzenburg,et al.  The role of the capsaicin receptor TRPV1 and acid-sensing ion channels (ASICS) in proton sensitivity of subpopulations of primary nociceptive neurons in rats and mice , 2006, Neuroscience.

[69]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[70]  M. Piccart,et al.  Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863). , 2006, European journal of cancer.

[71]  R. Schiff,et al.  Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. , 2006, Endocrine-related cancer.

[72]  P. Smolewski.  Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway , 2006, Anti-cancer drugs.

[73]  E. T. Gawlinski,et al.  Acid-mediated tumor invasion: a multidisciplinary study. , 2006, Cancer research.

[74]  B. Druker,et al.  Targeted CML therapy: controlling drug resistance, seeking cure. , 2006, Current opinion in genetics & development.

[75]  G. Giaccone,et al.  Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies , 2005, Cancer.

[76]  E. Papp-Szabó,et al.  Microenvironmental influences on mutagenesis in mammary epithelial cells , 2005, International journal of cancer.

[77]  K. Lamborn,et al.  High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody , 2005, Clinical Cancer Research.

[78]  Dominik Wodarz,et al.  Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[79]  David Grimes,et al.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  O. Witte,et al.  Differential proton sensitivity of related G protein-coupled receptors T cell death-associated gene 8 and G2A expressed in immune cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[81]  K. Offit,et al.  Hereditary cancer predisposition syndromes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  P. Glazer,et al.  Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. , 2005, Mutation research.

[83]  D. DeMarini.  Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. , 2004, Mutation research.

[84]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[85]  S. Fulda,et al.  Targeting apoptosis pathways in cancer therapy. , 2004, Current cancer drug targets.

[86]  S. Atlas,et al.  Magnetic resonance image–guided proteomics of human glioblastoma multiforme , 2003, Journal of magnetic resonance imaging : JMRI.

[87]  Robert A Gatenby,et al.  Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies. , 2003, Molecular cancer therapeutics.

[88]  G. Shi,et al.  Functional genomics guided with MR imaging: mouse tumor model study. , 2003, Radiology.

[89]  P. Glazer,et al.  Decreased Expression of the DNA Mismatch Repair Gene Mlh1 under Hypoxic Stress in Mammalian Cells , 2003, Molecular and Cellular Biology.

[90]  Jin-Ming Yang,et al.  Acidic pH induces topoisomerase II-mediated DNA damage , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[91]  A. Giaccia,et al.  ATR/ATM Targets Are Phosphorylated by ATR in Response to Hypoxia and ATM in Response to Reoxygenation* , 2003, The Journal of Biological Chemistry.

[92]  Michael V Knopp,et al.  Microarray gene expression analysis of murine tumor heterogeneity defined by dynamic contrast-enhanced MRI. , 2002, Molecular imaging.

[93]  M V Knopp,et al.  Dynamic contrast-enhanced magnetic resonance imaging in oncology. , 2001, Topics in magnetic resonance imaging : TMRI.

[94]  W. Sly,et al.  Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. , 2001, The American journal of pathology.

[95]  K. Kinzler,et al.  Genetic instability and darwinian selection in tumours. , 1999, Trends in cell biology.

[96]  I. Fidler,et al.  Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[97]  Lindsay W. Turnbull,et al.  Dynamic Contrast Enhanced Magnetic Resonance Imaging of the Breast Is Superior to Triple Assessment for the Pre-Operative Detection of Multifocal Breast Cancer , 1999, Annals of Surgical Oncology.

[98]  A. Fayyazi,et al.  High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. , 1999, Cancer research.

[99]  Z. Ronai,et al.  Environmental factors as regulators and effectors of multistep carcinogenesis. , 1999, Carcinogenesis.

[100]  Natarajan Raghunand,et al.  In vivo imaging of extracellular pH using 1H MRSI , 1999, Magnetic resonance in medicine.

[101]  C. Cordon-Cardo,et al.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[102]  G. Lenoir,et al.  Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[103]  Rakesh K. Jain,et al.  Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.

[104]  P. Glazer,et al.  Genetic instability induced by the tumor microenvironment. , 1996, Cancer research.

[105]  M. Dewhirst,et al.  Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. , 1996, Cancer research.

[106]  F. Frouin,et al.  Radiologic assessment of intranodal vascularity in head and neck squamous cell carcinoma. Correlation with histologic vascular density. , 1996, Investigative radiology.

[107]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[108]  A. Nadas,et al.  Serum deprivation, but not inhibition of growth per se, induces a hypermutable state in Chinese hamster G12 cells. , 1996, Cancer research.

[109]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[110]  J. Tucker,et al.  Hprt mutants in a transplantable murine tumour arise more frequently in vivo than in vitro. , 1995, British Journal of Cancer.

[111]  R. Gillies,et al.  31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. , 1994, The American journal of physiology.

[112]  T. Morita,et al.  Clastogenicity of low pH to various cultured mammalian cells. , 1991, Mutation research.

[113]  L. Loeb,et al.  Mutator phenotype may be required for multistage carcinogenesis. , 1991, Cancer research.

[114]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.

[115]  R. Hill,et al.  Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[116]  S. Mirski,et al.  Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. , 1987, Cancer research.

[117]  R. Schimke,et al.  Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[118]  Christine Pourcel,et al.  Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma , 1980, Nature.

[119]  F. Jacob,et al.  Evolution and tinkering. , 1977, Science.

[120]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[121]  J. Wolff,et al.  Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. , 1948, The New England journal of medicine.

[122]  Ö. Winge.  Zytologische Untersuchungen über die Natur maligner Tumoren , 1930, Zeitschrift für Zellforschung und Mikroskopische Anatomie.

[123]  P. Abrahamsson,et al.  Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. , 2010, European urology.

[124]  J Nucl Med , 2010 .

[125]  J. Salk.  Clonal evolution in cancer , 2010 .

[126]  B. Frieden,et al.  Adaptive therapy. , 2009, Cancer research.

[127]  Robert J. Gillies,et al.  A microenvironmental model of carcinogenesis , 2008, Nature Reviews Cancer.

[128]  A A Sandberg,et al.  Chromosomal abnormalities in human neoplasia. , 1970, Annual review of medicine.